CAS: 1243262-17-0

A humanized monoclonal antibody that targets the N-terminal epitope of Notch ligand DLL4 (delta-like 4).

Demcizumab (OMP 21M18), an anti-DLL4 antibody, inhibits the Notch pathway and fights various cancers solo or with chemo.